Ad hoc

Biofrontera to take over the sales and marketing of Ameluz® in Spain from Allergan

Biofrontera AG / Keyword(s): Misc. matters / Ad hoc: Biofrontera to take over the sales and marketing of Ameluz® in Spain from Allergan . Ad hoc announcement according to § 15 WpHG. Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

• Change will be effected in March 2015

Key Account Manager for dermatology will transfer to Biofrontera

No financial obligations between the companies

New structure captures the full margin for Biofrontera

Leverkusen, 07 November 2014 - Biofrontera AG (FSE: B8F), the biopharmaceutical company focusing on skin cancer, announced today that it has agreed with Allergan SA to take over distribution (marketing and sales) activities for Ameluz^® and BF-RhodoLED^® in Spain.

Allergan is currently realigning its business strategy with a focus on three main business areas, Ophthalmology, Neuroscience and Medical Aesthetics. Allergan has successfully launched Ameluz^® in the Spanish market after having achieved all necessary local regulatory prerequisites, such as the determination of pricing and full reimbursement. Allergan has been very successful in getting a large number of Spanish hospitals to started using Ameluz^® for photodynamic therapy. Allergan will now work closely with Biofrontera to ensure a smooth transition of marketing and sales activities in Spain.

In connection with the transfer, Biofrontera is pleased to announce that Allergan's Key Account Manager for Dermatology will continue working with Ameluz^® and has therefore agreed to transfer to Biofrontera, acting as the nucleus of Biofrontera's future marketing and sales organization in Spain.

The new distribution arrangement will become effective in March 2015, allowing Biofrontera sufficient time to register Biofrontera Pharma GmbH as the Spanish distributor of Ameluz^® and prepare marketing and sales activities. The agreement does not create any financial obligation between the parties. This transfer will result in Biofrontera capturing the full margin as a direct vendor, which will significantly increase profitability for Biofrontera in respect of sales in Spain. Product revenues are expected to balance Biofrontera's further investment into marketing and sales in Spain within 12 months. Biofrontera appreciates all of Allergan's efforts in successfully launching Ameluz® in Spain, one of the most important European markets for photodynamic therapy.

Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen
ISIN: DE0006046113
WKN: 604611

contact: Biofrontera AG
Tel.: [phone], Fax.: [phone]
e-mail: [e-mail]

---

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Biofrontera AG via Globenewswire

HUG#1869697

--- End of Message ---

Biofrontera AG
Hemmelrather Weg 201 Leverkusen Germany

WKN: 604611;ISIN: DE0006046113;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Börse Berlin,
Freiverkehr in Bayerische Börse München,
Regulierter Markt in Frankfurter Wertpapierbörse,
Regulierter Markt in Börse Düsseldorf;